Table 3

Relative risk* of cancer overall in TNFi-treated patients with SpA from ARTIS and DANBIO (n=8703)† versus Swedish TNFi-naïve SpA patients (n=28 164)† and Swedish general population comparator subjects (n=131 687)† overall and in AS, PsA and SpA undifferentiated (UNS) separately 2001 to 2011

TNFi (DANBIO and ARTIS)-treated patients with SpA versus TNFi-naïveTNFi-treated (DANBIO and ARTIS) patients with SpA
versus general population
TNFi-naïve patients with SpA versus the general population
N cancers
TNFi-treated/TNFi-naïve
RR (95% CI)N cancers
TNFi-treated/general population
RR (95% CI)N cancers
TNFi naïve/general population
RR (95% CI)
All SpA147/11880.8 (0.7 to 1.0)147/51530.9 (0.7 to 1.0)1188/51531.1 (1.0 to 1.2)
AS53/3100.8 (0.6 to 1.1)53/12960.9 (0.7 to 1.2)310/12961.1 (1.0 to 1.3)
PsA71/7220.9 (0.7 to 1.1)71/32270.9 (0.7 to 1.1)722/32271.0 (0.9 to 1.1)
SpA UNS23/2000.9 (0.6 to 1.3)23/9790.8 (0.6 to 1.3)202/9791.0 (0.8 to 1.2)
  • *Age-standardised and sex-standardised incidence ratio (RR) with 95% CIs.

  • †DANBIO and ARTIS=TNFi-treated SpA, persons-years=33 908, Swedish TNFi-naïve patients with SpA, person-years=182 136, Swedish general population comparator subjects, person-years=862 380.

  • ARTIS, Anti-Rheumatic Therapy in Sweden; AS, ankylosing spondylitis; DANBIO, Danish biologics register; PsA, psoriatic arthritis; RR, relative risk; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.